Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Cancer Research

• Publication date

  1991-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  PMID 1933854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen.

  1990cited by this paper
• A comparative study of the interaction of oestradiol and the steroidal pure antioestrogen, ICI 164,384, with the molybdate-stabilized oestrogen receptor.

  1990cited by this paper
• Biology and mode of action of pure antioestrogens.

  1989cited by this paper
• Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent.

  1989cited by this paper
• Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action

  1988cited by this paper
• Novel antioestrogens without partial agonist activity.

  1988cited by this paper
• Biology and mode of action of pure antioestrogens.

  1988cited by this paper
• Adjuvant tamoxifen in the management of operable breast cancer : Scottish Trial

  1987cited by this paper
• Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

  1987cited by this paper
• Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response.

  1986cited by this paper
• Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells.

  1984cited by this paper
• The pharmacology and clinical uses of tamoxifen.

  1984cited by this paper
• An evaluation of tamoxifen as a partial agonist by classical receptor theory--an explanation of the dual action of tamoxifen.

  1984cited by this paper
• Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.

  1983cited by this paper
• Antagonism of estrogen action with a new benzothiophene derived antiestrogen.

  1983cited by this paper
• Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.

  1983cited by this paper
• Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience.

  1982cited by this paper
• Antiestrogen basicity--activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-butene (tamoxifen, Nolvadex) having altered basicity.

  1982cited by this paper
• Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience.

  1982cited by this paper
• Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.

  1981cited by this paper
• Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model.

  1980cited by this paper
• EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPS

  1980cited by this paper
• Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice.

  1980cited by this paper
• Tamoxifen in advanced breast cancer.

  1978cited by this paper
• Tamoxifen flare in advanced breast cancer.

  1978cited by this paper
• Evaluation of tamoxifen dose in advanced breast cancer: a progress report.

  1976cited by this paper
• A new derivative of triphenylethylene: effect on implantation and mode of action in rats.

  1967cited by this paper

• Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer

  2024cites this paper
• Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations

  2017cites this paper
• An overview of current and emerging SERMs.

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• Selective estrogen receptor modulators: tissue specificity and clinical utility

  2014cites this paper
• Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1.

  2013cites this paper
• Use of preclinical and early clinical data for dose selection of a selective estrogen receptor modulator toremifene in treatment of breast cancer

  2012cites this paper
• Emerging Selective Estrogen Receptor Modulators

  2012cites this paper
• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• Clinical Utility of New Antiestrogens

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

  2009cites this paper
• Histologic changes in ovary, uterus, vagina, and mammary gland of mature beagle dogs treated with the SERM idoxifene.

  2007cites this paper
• Endothelial Injury and Cell Cycle Re-Entry

  2006cites this paper
• Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

  2006cites this paper
• Estrogen receptors as therapeutic targets in breast cancer.

  2006cites this paper
• Moduladores selectivos de los receptores estrogénicos (SERMs): bioquímica, farmacología y aplicación clínica en ginecología

  2005cites this paper
• Resveratrol as a Phytoestrogen

  2005cites this paper
• The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

  2004cites this paper
• Sequencing of Endocrine Therapy in Postmenopausal Women with Advanced Breast Cancer

  2004cites this paper
• Antiestrogens – Tamoxifen, SERMs and Beyond

  2004cites this paper
• A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen

  2004cites this paper
• Structure-based drug design: synthesis, crystal structure, biological evaluation and docking studies of mono- and bis-benzo[b]oxepines as non-steroidal estrogens.

  2003cites this paper
• Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer.

  2003influential citation
• De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor.

  2003cites this paper
• De novo design, synthesis and evaluation of a non-steroidal diphenylnaphthyl propylene ligand for the estrogen receptor.

  2003cites this paper
• Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen.

  2003cites this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

  2003cites this paper
• Critical Review and Evaluation of the Uterotrophic Bioassay for the Identification of Possible Estrogen Agonists and Antagonists: In Support of the Validation of the OECD Uterotrophic Protocols for the Laboratory Rodent

  2002cites this paper
• Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor α

  2002cites this paper
• SERMs: current status and future trends.

  2002cites this paper
• Endocrine Treatment of Advanced Breast Cancer: Selective Estrogen-Receptor Modulators (SERMs)

  2002cites this paper
• Fulvestrant (Faslodex™): current status in the therapy of breast cancer

  2002cites this paper
• Endocrine therapy in the treatment of metastatic breast cancer.

  2001cites this paper
• Tamoxifen to raloxifene and beyond.

  2001cites this paper
• Preliminary experience with pure antiestrogens.

  2001cites this paper
• Comparison between liquid chromatography-time of-flight mass spectrometry and selected reaction monitoring liquid chromatography-mass spectrometry for quantitative determination of idoxifene in human plasma.

  2001cites this paper
• Antiestrógenos: mecanismo de acción y aplicaciones clínicas

  2001cites this paper
• LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.

  2001cites this paper
• Selected reaction monitoring LC-MS determination of idoxifene and its pyrrolidinone metabolite in human plasma using robotic high-throughput, sequential sample injection.

  2001cites this paper
• [Antiestrogens: mechanism of action and clinical applications].

  2001cites this paper
• Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.

  2001cites this paper
• Antiestrógenos: mecanismo de acción y aplicaciones clínicas

  2001cites this paper
• Tamoxifen versus the newer SERMs: what is the evidence?

  2000cites this paper
• The endometrial effects of SERMs.

  2000cites this paper
• Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.

  2000cites this paper
• Selective estrogen receptor modulators: structure, function, and clinical use.

  2000cites this paper
• Is ICI 182,780 an antiprogestin in addition to being an antiestrogen?

  2000cites this paper
• Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.

  2000cites this paper
• Selective Estrogen Receptor Modulator Idoxifene Inhibits Smooth Muscle Cell Proliferation, Enhances Reendothelialization, and Inhibits Neointimal Formation In Vivo After Vascular Injury

  2000cites this paper
• Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells.

  1999cites this paper
• Clinical Pharmacology of Selective Estrogen Receptor Modulators

  1999cites this paper
• [Effect of selective estrogen receptor modulators on estrogen-sensitive tissues].

  1999cites this paper
• The evolving role of specific estrogen receptor modulators (SERMs)

  1999cites this paper
• The Use of Antiestrogens in the Postmenopausal Woman

  1999cites this paper
• Pharmacology and Use of Antiestrogens in Treatment and Chemoprevention of Breast Cancer

  1999cites this paper
• Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis.

  1999cites this paper
• Selective estrogen receptor modulators: Women's panacea for the next millennium?

  1999cites this paper
• Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.

  1999influential citation
• Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.

  1998cites this paper
• Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression.

  1998cites this paper
• Pharmacological enhancement of gamma-knife response: An in vitro study.

  1998cites this paper
• Basic guide to the mechanisms of antiestrogen action.

  1998cites this paper
• New Antiestrogens in Breast Cancer: A Review

  1998cites this paper
• Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal.

  1998cites this paper
• An evaluation of the novel selective estrogen receptor modulator, idoxifene, for effects on reproduction in rats and rabbits.

  1998influential citation
• Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.

  1997cites this paper
• The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance.

  1997influential citation
• Acquired tamoxifen resistance in human breast cancer--potential mechanisms and clinical implications.

  1997cites this paper
• Clinical potential of new antiestrogens.

  1997cites this paper
• Antiestrogens: future prospects.

  1997influential citation
• Molecular mechanisms and future uses of antiestrogens.

  1997cites this paper
• Recent advances in endocrine therapy of breast cancer

  1997cites this paper
• Nonestrogen management of menopausal symptoms.

  1997cites this paper
• Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.

  1997cites this paper
• Future Developments in Adjuvant and Palliative Systemic Endocrine Therapies

  1996cites this paper
• Current and future roles of adjuvant endocrine therapy in the management of early carcinoma of the breast.

  1996cites this paper
• New endocrine therapies for breast cancer.

  1996cites this paper
• Endocrine treatment of advanced breast cancer.

  1996cites this paper
• Adjuvant Therapy of Breast Cancer V

  1996cites this paper
• Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats.

  1996cites this paper
• Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer.

  1995cites this paper
• Idoxifene: report of a phase I study in patients with metastatic breast cancer.

  1995cites this paper
• Pharmacokinetics and biodistribution of radiolabelled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy.

  1995cites this paper
• Estrogen receptor blockade by the pure antiestrogen, ZM 182780, induces death of pituitary tumour cells.

  1995cites this paper
• Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.

  1995cites this paper
• Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384.

  1995cites this paper
• Mechanisms of action of endocrine treatment in breast cancer.

  1995cites this paper
• 4′-Substituted analogues of idoxifene: Antiestrogens and calmodulin antagonists

  1995cites this paper
• N. C. A. radioiodination of idoxifene

  1995cites this paper
• Preclinical Characterisation of Radiolabelled Idoxifene

  1995cites this paper
• Alternate antiestrogens and approaches to the prevention of breast cancer

  1995cites this paper
• Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo.

  1995cites this paper
• AN EFFICIENT, LARGE-SCALE SYNTHESIS OF IDOXIFENE {(E)-1-[4-[2-(N-PYRROLIDINO)ETHOXY]PHENYL]-1-(4-IODOPHENYL)-2-PHENYL-1-BUTENE}

  1994cites this paper
• Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues.

  1994cites this paper
• Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.

  1994cites this paper
• Synthesis of 4‐stannylated tamoxifen analogues; useful precursors to radiolabelled idoxifene and aziridinyl 4‐iodotamoxifen

  1994cites this paper
• A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism.

  1994cites this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives.

  1994cites this paper